{
    "nctId": "NCT02253251",
    "briefTitle": "Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment",
    "officialTitle": "Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment",
    "overallStatus": "RECRUITING",
    "conditions": "Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 15000,
    "primaryOutcomeMeasure": "Measuring the prevalence of the KRAS-variant in certain populations Prevalence of the KRAS-variant in BRCA negative breast cancer patients",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Personal or family history of cancer\n* Personal history of endometriosis, or autoimmunity\n\nExclusion Criteria:\n\n* Younger than 18\n* Non-english speaking and unable to understand and sign the consent",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}